Underrepresentation of ethnic minorities in hypertension research—a survey of enablers and barriers among South Asian and African communities in Glasgow

[1] Khunti K(2017)Representation of people of South Asian origin in cardiovascular outcome trials of glucose-lowering therapies in type 2 diabetes Diabet Med 34 64-68

[2] Bellary S(2020)Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process Trials 21 694-93

[3] Karamat MA(2005)External validity of randomised controlled trials: “to whom do the results of this trial apply?” Lancet 365 82-1254

[4] Patel K(2016)Life expectancy of different ethnic groups using death records linked to population census data for 4.62 million people in Scotland J Epidemiol Community Health 70 1251-584

[5] Patel V(2011)Recruiting South Asians to a lifestyle intervention trial: experiences and lessons from PODOSA (Prevention of Diabetes & Obesity in South Asians) Trials 12 220-3104

[6] Jones A(2018)Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms Can J Cardiol 34 575-BB50

[7] Witham MD(2018)2018 ESC/ESH Guidelines for the management of arterial hypertension Eur Heart J 39 3021-D1D3

[8] Anderson E(2021)May Measurement Month 2019: an analysis of blood pressure screening results from the United Kingdom and Republic of Ireland Eur Heart J Suppl 23 B147-108

[9] Carroll C(2019)May Measurement Month 2017: an analysis of blood pressure screening results from the United Kingdom and the Republic of Ireland-Europe Eur Heart J Suppl 21 D121-642

[10] Dark PM(2018)A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: the comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program-AIM-HY INFORM trial Am Heart J 204 102-e31

[1] Khunti K(2017)Representation of people of South Asian origin in cardiovascular outcome trials of glucose-lowering therapies in type 2 diabetes Diabet Med 34 64-68

[2] Bellary S(2020)Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process Trials 21 694-93

[3] Karamat MA(2005)External validity of randomised controlled trials: “to whom do the results of this trial apply?” Lancet 365 82-1254

[4] Patel K(2016)Life expectancy of different ethnic groups using death records linked to population census data for 4.62 million people in Scotland J Epidemiol Community Health 70 1251-584

[5] Patel V(2011)Recruiting South Asians to a lifestyle intervention trial: experiences and lessons from PODOSA (Prevention of Diabetes & Obesity in South Asians) Trials 12 220-3104

[6] Jones A(2018)Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms Can J Cardiol 34 575-BB50

[7] Witham MD(2018)2018 ESC/ESH Guidelines for the management of arterial hypertension Eur Heart J 39 3021-D1D3

[8] Anderson E(2021)May Measurement Month 2019: an analysis of blood pressure screening results from the United Kingdom and Republic of Ireland Eur Heart J Suppl 23 B147-108

[9] Carroll C(2019)May Measurement Month 2017: an analysis of blood pressure screening results from the United Kingdom and the Republic of Ireland-Europe Eur Heart J Suppl 21 D121-642

[10] Dark PM(2018)A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: the comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program-AIM-HY INFORM trial Am Heart J 204 102-e31